354 related articles for article (PubMed ID: 19028457)
1. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
2. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
3. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
5. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
6. Management of medullary thyroid cancer.
Ball DW
Minerva Endocrinol; 2011 Mar; 36(1):87-98. PubMed ID: 21460789
[TBL] [Abstract][Full Text] [Related]
7. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
[TBL] [Abstract][Full Text] [Related]
8. RET inhibition: implications in cancer therapy.
Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
[TBL] [Abstract][Full Text] [Related]
9. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
10. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
Santoro M; Carlomagno F
Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):42-52. PubMed ID: 16932252
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
12. New approaches to thyroid cancer.
Cohen EE
Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
[No Abstract] [Full Text] [Related]
13. Inhibition of RET tyrosine kinase by SU5416.
Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
[TBL] [Abstract][Full Text] [Related]
14. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
15. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.
Drosten M; Pützer BM
Nat Clin Pract Oncol; 2006 Oct; 3(10):564-74. PubMed ID: 17019434
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
19. RET/PTC oncoproteins: molecular targets of new drugs.
Lanzi C; Cassinelli G; Cuccuru G; Zanchi C; Laccabue D; Zunino F
Tumori; 2003; 89(5):520-2. PubMed ID: 14870776
[TBL] [Abstract][Full Text] [Related]
20. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]